These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 18216370)

  • 1. The normal hematocrit study--follow-up.
    Besarab A; Goodkin DA; Nissenson AR;
    N Engl J Med; 2008 Jan; 358(4):433-4. PubMed ID: 18216370
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
    N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 5. Anaemia of CKD--the CHOIR study revisited.
    Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D
    Nephrol Dial Transplant; 2007 Jul; 22(7):1806-10. PubMed ID: 17420166
    [No Abstract]   [Full Text] [Related]  

  • 6. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
    Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
    Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 9. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythropoietin for end-stage renal disease.
    Adamson JW; Eschbach JW
    N Engl J Med; 1998 Aug; 339(9):625-7. PubMed ID: 9718384
    [No Abstract]   [Full Text] [Related]  

  • 11. Timely correction of anemia at the initiation of dialysis. Case study of the anemic patient.
    Breiterman-White R
    Nephrol Nurs J; 2002 Oct; 29(5):469-72. PubMed ID: 12434453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.
    Cotter DJ; Stefanik K; Zhang Y; Thamer M; Scharfstein D; Kaufman J
    J Clin Epidemiol; 2004 Oct; 57(10):1086-95. PubMed ID: 15528060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC; Temple RM; Kwan JT
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
    Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
    Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.
    Jones M; Schenkel B; Just J
    Int J Cardiol; 2005 Apr; 100(2):253-65. PubMed ID: 15823633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin trials: randomised controlled trials don't always mimic observational data.
    Roger SD; Levin A
    Nephrol Dial Transplant; 2007 Mar; 22(3):684-6. PubMed ID: 17210590
    [No Abstract]   [Full Text] [Related]  

  • 19. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
    Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
    Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M; Vetter A; Thyroff-Friesinger U;
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.